Compare · ABBV vs CPRX
ABBV vs CPRX
Side-by-side comparison of AbbVie Inc. (ABBV) and Catalyst Pharmaceuticals Inc. (CPRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and CPRX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $449.63B, about 116.6x CPRX ($3.85B).
- Over the past year, ABBV is up 34.5% and CPRX is up 49.6% - CPRX leads by 15.2 points.
- CPRX has been more active in the news (42 items in the past 4 weeks vs 23 for ABBV).
- ABBV has more recent analyst coverage (25 ratings vs 7 for CPRX).
- Company
- AbbVie Inc.
- Catalyst Pharmaceuticals Inc.
- Price
- $254.52+0.06%
- $31.49+0.03%
- Market cap
- $449.63B
- $3.85B
- 1M return
- +14.38%
- +0.41%
- 1Y return
- +34.48%
- +49.63%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2006
- News (4w)
- 23
- 42
- Recent ratings
- 25
- 7
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS) and myasthenia gravis; and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Latest ABBV
- Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
- SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
- SEC Form 4 filed by Director Rapp Edward J
- SEC Form 4 filed by Director Quaggin Susan E
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- FDA Approval for SKYRIZI issued to ABBVIE INC
Latest CPRX
- Chief HR Officer Russo Gregg returned $14,994 worth of shares to the company (476 units at $31.50), closing all direct ownership in the company (SEC Form 4) (withholding tax)
- Chief Legal Officer Elsbernd Brian returned $7,638,782 worth of shares to the company (242,501 units at $31.50), closing all direct ownership in the company (SEC Form 4) (for tax liability)
- SEC Form 4 filed by Director Curran Daniel J. to cover taxes
- Director Thompson Tamar returned $118,850 worth of shares to the company (3,773 units at $31.50), closing all direct ownership in the company (SEC Form 4) to satisfy withholding tax
- Chief Op. & Scientific Officer Miller Steve returned $34,454,794 worth of shares to the company (1,093,803 units at $31.50), closing all direct ownership in the company (SEC Form 4) (tax withholding)
- Director Tierney David S returned $12,074,391 worth of shares to the company (383,314 units at $31.50), closing all direct ownership in the company (SEC Form 4) (tax liability)
- Chief Strategy Officer Sundaram Preethi returned $1,726,326 worth of shares to the company (54,804 units at $31.50), closing all direct ownership in the company (SEC Form 4) to cover withholding tax
- Chairman of Board of Directors Mcenany Patrick J returned $131,404,108 worth of shares to the company (4,171,559 units at $31.50), closing all direct ownership in the company (SEC Form 4) (for tax liability)
- President and CEO Daly Richard J returned $8,544,879 worth of shares to the company (271,266 units at $31.50), closing all direct ownership in the company (SEC Form 4) (for withholding tax)
- Chief Commercial Officer Del Carmen Jeffrey returned $451,616 worth of shares to the company (14,337 units at $31.50), closing all direct ownership in the company (SEC Form 4) (for tax liability)